Safety and feasibility of intravenous fresh adipose-derived mesenchymal stem cells in secondary progressive multiple sclerosis: phase I/IIa clinical results - PubMed
9 hours ago
- #mesenchymal stem cells
- #clinical trial
- #multiple sclerosis
- Study evaluated safety and clinical effects of fresh autologous adipose-derived mesenchymal stem cells (AT-MSCs) in secondary progressive multiple sclerosis (SPMS).
- 10 female SPMS patients received high-dose intravenous AT-MSCs in two doses, seven days apart.
- No serious adverse events were reported over 9 months post-transplantation.
- AT-MSC therapy reduced T2-FLAIR lesion number and volume, improved EDSS scores, and enhanced psychological outcomes.
- Therapy increased regulatory T-cell proportions and anti-inflammatory cytokine expression while decreasing inflammatory cytokines.
- Findings suggest AT-MSCs are safe and may offer clinical benefits for SPMS patients.